Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Xbrane Biopharma AB informs about presentations where the company participates on February 19
By: Nasdaq / GlobeNewswire - 15 Feb 2019Back to overview list

Press release
2019-02-15

During Tuesday, February 19, Xbrane will attend two presentations that will also be webcasted live. Below follows information about the events and links to the webcasts that will also be available on the company's website afterwards.

Börsveckan's SME day
Time: 19 February, 8.30-9.00 AM.
Place: Operaterrassen, Karl XII:s torg, Stockholm
The SME day is a collaboration between Financial Hearings and Börsveckan.
Xbrane will present the company followed by Q&A moderated by Lars Frick analyst at Börsveckan.
The presentation will be in Swedish.
For registration visit www.financialhearings.com
Link to live webcast: https://tv.streamfabriken.com/2019-02-19-xbrane-biopharma

Vator Securities Key Opinion Leader event
Time: 19 February, 3.00-4.00 PM
The presentation will be in English.
Vator Securities arranges a KOL-event on the theme "Building a Successful Biosimilars Company". Key notespeakers are Manfred Weiler and Laszlo Bekesi from Syneos Health, experts within Biosimilars respectively Ophthalmology.
Link to live webcast: https://youtu.be/XA0dCWOBfjI

For further information, please contact:
Martin Åmark
CEO/IR
M: +46(0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen
CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (corp@avanza.se, +46 (0)8 409 421 20). For more information see www.xbrane.com.

Attachment

Related companies:Xbrane Biopharma AB
Copyright 2019 Nasdaq / GlobeNewswire Back to overview list
to the top ↑